An extended study after a primary trial supports using the anti-amyloid drug lecanemab (Leqembi) for up to 36 months in ...

Leqembi — sold through a partnership between Eisai Co. and Cambridge-based Biogen — is one of the first medications approved ...

Within the past few years, the FDA approved two groundbreaking drugs that in trials were shown to reduce brain plaque by 27% ...

Eisai/Biogen’s Leqembi (lecanemab) was fully approved in the US in July 2023, and Eli Lilly’s Kisunla (donanemab) in July ...

Leqembi is an infusion therapy approved by the Food and Drug Administration in 2023. It targets and removes the beta-amyloid ...

Eli Lilly (NYSE: LLY) has emerged as one of the hottest stocks in the GLP-1 realm -- underscored by its combination of blockbuster treatments, Mounjaro and Zepbound. Where to invest $1,000 right now?

32,355 people played the daily Crossword recently. Can you solve it faster than others?32,355 people played the daily ...

The European Union's drugs regulator on Friday rejected Eli Lilly's Alzheimer's drug, saying the treatment's small impact on slowing cognitive decline was not large enough to outweigh the risk of ...

The European Union’s CHMP said that the benefits of the drug, already approved in the U.S., do not outweigh the risk of potentially fatal brain swelling and bleeding.

Biogen enhances its portfolio and margins amidst market challenges and competition. Click here to find out why BIIB stock is a Hold.

A European health committee has rejected Eli Lilly’s Alzheimer’s drug, Kisunla, because of safety concerns about possible ...

Following the launch of the first disease-modifying therapies for Alzheimer’s disease, a key theme at the AD/PD 2025 ...